disappointing preliminary results for a phase three trial of a lung cancer treatment.
AstraZeneca said it slowed progression of the cancer, but the data for overall survival was "not mature" and the results were not statistically significant. The trial will continue to assess overall survival with greater maturity, the company said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »